Beyond Average: New Benchmarks for Excellence in Pediatric Emergency Care

Child's forearm in a white cast resting on a pillow in a hospital bed, with the other hand holding a teddy bear, under the title Beyond Average: New benchmarks for pediatric emergency care

Article reviewed: Alpern ER, Ramgopal S, Olsen CS, et al. Achievable benchmarks of care in pediatric emergency departments. JAMA Netw Open. 2026;9(5):e2613391
DOI: 10.1001/jamanetworkopen.2026.13391  |  PubMed: PMID 42154467

Emergency departments routinely track quality measures: door-to-provider time, length of stay, return visits, medication administration, and dozens of others. However, knowing your performance is only half the equation. The harder question is what benchmark should you be aiming for?

Comparing with the national average may tell you where you stand, but “average” is not necessarily synonymous with good care. At the other extreme, setting every target at 100% adherence or zero failures may be unrealistic, and can direct substantial resources toward marginal gains.

A recent study by Alpern and colleagues in JAMA Network Open offers a different approach [1]. Using more than 5.3 million pediatric emergency department visits from the Pediatric Emergency Care Applied Research Network (PECARN) Registry, the investigators established Achievable Benchmarks of Care (ABCs) for common measures of pediatric emergency care. Rather than defining excellence theoretically, they asked a pragmatic question: What level of performance are the best-performing clinicians already achieving in real-world emergency departments?

The Study

The investigators performed a cross-sectional analysis of 5,302,587 visits from 2017 through 2024 across 12 emergency departments participating in the PECARN Registry: nine pediatric EDs and three affiliated community sites. The analysis included 925 clinicians. PECARN has also published a brief summary of the study [2].

The authors evaluated measures spanning several important domains of pediatric emergency care:

  • Initial assessment and vital-sign documentation
  • Timeliness and ED throughput
  • Return visits and other quality and safety measures
  • Asthma care
  • Pain assessment and treatment
  • Antibiotic stewardship

Many of these are familiar quality metrics already endorsed or prioritized by organizations involved in pediatric emergency care. The important innovation was not the measures themselves. It was how the target for each measure was established.

What Is an “Achievable Benchmark”?

Instead of using the mean or median as the standard, the investigators identified the highest-performing clinicians who collectively cared for approximately 10% of eligible visits. Performance among this high-achieving group was then used to calculate the benchmark.

For binary measures, the investigators used an adjusted performance fraction designed to prevent clinicians with small numbers of eligible encounters from disproportionately influencing the benchmark. Continuous measures were ranked using median performance. The result is a target grounded in achievable excellence. The distinction matters. Whereas the mean tells an ED what everyone else is doing, an ABC provides evidence of what high-performing clinicians are already capable of doing under real clinical conditions.

The table below shows selected measures from a condensed list provided by the study’s lead author, chosen as the most important or interesting targets for change.

Performance measure Achievable benchmark
ED flow (throughput)
Time to provider, all patients 20 min
ESI 2 13 min
ESI 3 19 min
ESI 4 22 min
ED length of stay, all patients 114 min
Discharged 110 min
Admitted or transferred 268 min
Clinical care
Systemic corticosteroids for asthma 97.8%
Time to first beta-agonist for asthma 29 min
≥2-point pain reduction with long-bone fracture 80.5%
After the visit
Return visit within 48 hours 1.6%

Where Is the Opportunity to Improve?

Performance was not uniform across sites. For example, the proportion of children with long-bone fractures achieving at least a 2-point reduction in pain ranged from 61.4% to 92.6% across sites. Systemic corticosteroid administration for asthma ranged from 93.1% to 99.2%. Vital-sign documentation also showed substantial variation. In contrast, return visits resulting in admission and antibiotic stewardship showed relatively little variation.

That pattern may offer important direction for quality improvement. Measures that are relatively close to the clinician’s locus of control, such as asthma treatment and fracture pain management, showed meaningful differences between average site performance and what the site’s best-performing clinicians could achieve. That changes the quality-improvement conversation. If clinicians in the same ED, caring for similar patients within the same system, are consistently achieving better performance, the question becomes less “Can we do this?” and more “What are they doing differently, and how can we make that the default?”

Throughput Is Different

Door-to-provider time and length of stay deserve more cautious consideration. The study found substantial variation in throughput benchmarks between sites and between pediatric EDs and affiliated community settings. Interestingly, throughput performance worsened over the study period.

Unlike giving corticosteroids for an asthma exacerbation, ED length of stay is only partly controlled by an individual clinician. Crowding, staffing, boarding, diagnostic resources, consultation availability, inpatient capacity, and patient volume all can influence throughput. The authors appropriately note that future benchmarks may need to account for volume and capacity.

For example, a 110-minute benchmark for a discharged pediatric patient should not automatically become an inflexible performance mandate for every ED. It is better interpreted as a reference point: this level of performance has been demonstrated, and a substantial gap from it should prompt examination of the systems contributing to that gap.

Why Benchmarking Against “Average” Isn’t Enough

Quality dashboards frequently compare a clinician or department with an institutional or national mean. That approach is intuitive but has an obvious weakness: the average describes current performance; it does not necessarily define desirable performance.

Imagine an ED with a median time to provider of 38 minutes. Learning that the network average is 36 minutes tells the department that it is slightly slower than its peers. Learning that high-performing clinicians and systems can achieve approximately 20 minutes asks a much more useful question: what would have to change to close that gap?

The same concept applies to clinical care. An asthma corticosteroid benchmark of 97.8% is not an aspirational number invented by a committee. It reflects performance that clinicians in actual emergency departments have demonstrated.

ABCs therefore occupy a useful space between two imperfect targets:

“Be average” ← Achievable excellence → “Be perfect.”

A Benchmark Is a Starting Point, not a Report Card

There are important limitations. The PECARN Registry sites are predominantly pediatric centers, along with affiliated community sites. They do not represent the general EDs that care for most children nationally. Differences in pediatric volume, staffing, resources, geography, and pediatric readiness may affect whether a particular benchmark is immediately attainable in another setting. The study also relies on electronic health record data. Documentation does not always represent care, and EHR-derived measures cannot capture every element of clinical judgment or patient outcome.

These benchmarks therefore should not be interpreted as universal thresholds separating “good” from “bad” EDs, or good from bad clinicians. They are something more useful: empirical targets showing what high-performing clinicians and systems have demonstrated is possible.

The Bottom Line

Emergency medicine has no shortage of quality measures. What has often been missing is a meaningful answer to the question, “What should our target be?” This article provides one approach. By deriving benchmarks from high performers across more than 5.3 million pediatric ED encounters, the study team moves the target away from both average performance and theoretical perfection and toward achievable excellence.

For clinicians and ED leaders, the most useful question may not be whether your department meets every benchmark tomorrow. Instead, look at the measures where your performance differs most from what high-performing clinicians have already demonstrated. Determine which gaps are driven by individual practice and which are driven by systems. Then ask: What is keeping excellent care from becoming our usual care?

References

  1. Alpern ER, Ramgopal S, Olsen CS, et al; PECARN Registry Study Group. Achievable benchmarks of care in pediatric emergency departments. JAMA Netw Open. 2026;9(5):e2613391. PMID: 42154467. doi:10.1001/jamanetworkopen.2026.13391
  2. Woods JM. What excellent care looks like: new benchmarks. Pediatric Emergency Care Applied Research Network (PECARN). Published June 23, 2026. https://pecarn.org/pecarn_news/what-excellent-care-looks-like-new-benchmarks/
By |2026-10-14T23:51:32-07:00Oct 15, 2026|Administrative, Pediatrics|

Pediatric Pneumonia Without Routine Chest X-Rays: How Much Weight Should We Give the Lung Exam?

Two diverse clinicians take turns listening to a child's lungs from behind while a caregiver's hand rests on the child's arm

Article reviewed: Hooli S, Reeder R, Cutler L, et al. Reliability of Physical Examination Findings in Youths Diagnosed With Pneumonia. JAMA Netw Open. 2026;9(8):e2630074
DOI: 10.1001/jamanetworkopen.2026.30074  |  PubMed: PMID 42623068

Have you stood at the bedside while the resident, nurse, and student each described a different lung examination? Someone heard focal crackles. Someone else heard coarse breath sounds. The next clinician heard clear lungs. The PECARN PedCAPS (Pediatric Community-Acquired Pneumonia Severity) study suggests that this familiar disagreement is common.

In a new PECARN PedCAPS analysis published in JAMA Network Open, two clinicians independently examined the same 252 children with community-acquired pneumonia (CAP). No individual physical examination finding met the study’s prespecified reliability standard [1]. A single lung sound should not decide the diagnosis of pneumonia.

This creates a clinical dilemma.

The Pediatric Infectious Diseases Society (PIDS)/Infectious Diseases Society of America (IDSA) guidelines advise against routine chest radiography to confirm suspected CAP in children well enough for outpatient treatment [2]. However, the clinician must still decide whether CAP is likely enough to treat. That decision depends heavily on the history and physical examination, even though no individual symptom or sign is sufficiently sensitive or specific and clinicians may interpret the same lung sounds differently [3].

How do we then diagnose outpatient CAP without reflexively ordering an x-ray?

Study Design

This planned reliability analysis was nested within the ongoing prospective PECARN PedCAPS study cohort. Investigators enrolled children ages 3 months through 17 years with clinician-diagnosed CAP at seven academic pediatric EDs. Two attending physicians, advanced practice clinicians, or PEM fellows independently examined each child within 60 minutes. The clinicians completed identical standardized forms but received no special training in how to define the examination findings.

The study population limits how far we can take the results. Nearly all participants, 249 of 252 (98.8%), had pneumonia supported by chest radiography, and 128 (50.8%) were hospitalized. This selected group had established CAP and differs from the undifferentiated population of children presenting with cough, fever, or respiratory distress.

Investigators measured raw agreement and Fleiss κ for the following:

  • Altered mental status
  • Capillary refill
  • Grunting
  • Retractions or accessory muscle use
  • Auscultatory lung findings:
    • Wheezing
    • Decreased breath sounds
    • Crackles or rales
    • Rhonchi or coarse breath sounds

Acceptable reliability required the lower bound of the κ 95% confidence interval to be at least 0.40.

Results

No finding passed the prespecified threshold. Wheezing and retractions performed best, but only reached moderate agreement:

  • Wheezing: κ = 0.50 (95% CI 0.39-0.62), with 82% raw agreement
  • Retractions or accessory muscle use: κ = 0.49 (95% CI 0.37-0.60), with 78% raw agreement
  • Crackles or rales: κ = 0.21 (95% CI 0.11-0.31), with 55% raw agreement
  • Rhonchi or coarse breath sounds: κ = 0.18 (95% CI 0.08-0.28), with 56% raw agreement
  • Decreased breath sounds: κ = 0.11 (95% CI 0.02-0.20), with 46% raw agreement

When wheezing was simplified to present or absent without asking clinicians to distinguish focal from diffuse findings, κ improved to 0.58. This suggests that localization added another layer of disagreement.

Reliability did not differ significantly between the 124 children discharged home and the 128 hospitalized. The analyses by age, race, and clinician knowledge of chest radiograph results were underpowered and should not be described as showing equivalence across those groups.

Altered mental status, delayed capillary refill, and grunting were uncommon. Their high overall raw agreement largely reflected agreement that the findings were absent. When at least one examiner documented one of these findings, agreement that it was present was low. Clinicians should still treat altered mental status and grunting as concerning when present.

How to Diagnose Without a Routine Chest X-Ray?

Reliability and diagnostic accuracy are different questions. This study shows that clinicians frequently disagree about examination findings in children already diagnosed with CAP. It did not measure the sensitivity, specificity, or likelihood ratios of those findings among all children with possible pneumonia. Because almost every participant had radiographic pneumonia, it also cannot determine how auscultation performs in the less selected population we evaluate on shift.

The PIDS/IDSA guideline discourages routine imaging while preserving selective imaging when uncertainty matters. It does, however, recommend a chest radiograph when a child has suspected or documented hypoxemia, significant respiratory distress, or failure of initial antibiotic therapy [2]. In a well-appearing child without those features, a clinician should holistically combine the history with measured respiratory rate, oxygen saturation, work of breathing, overall appearance, serial examinations, and a reliable follow-up plan. One reported crackle, focal decrease in breath sounds, or coarse sound should not become the diagnostic push for radiographs.

“Our results emphasize the need to look at multiple features of the clinical presentation rather than exam findings in isolation when making the diagnosis of pneumonia.”

Todd A. Florin, MD, MSCE, senior author of this 2026 JAMA publication

Bottom Line

Keep listening to the lungs, but do not let one auscultatory finding decide whether a child has pneumonia. When examinations conflict and the uncertainty would change management, return to the full clinical picture and obtain additional information selectively.

References

  1. Hooli S, Reeder R, Cutler L, et al. Reliability of Physical Examination Findings in Youths Diagnosed With Pneumonia. JAMA Netw Open. 2026;9(8):e2630074. PMID: 42623068. doi:10.1001/jamanetworkopen.2026.30074
  2. Bradley JS, Byington CL, Shah SS, et al. The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53(7):e25-e76. PMID: 21880587. doi:10.1093/cid/cir531
  3. Lipsett SC, Neuman MI. Rethinking Auscultation for Pediatric Pneumonia: Do My Ears Deceive Me? JAMA Netw Open. 2026;9(8):e2630083. PMID: 42623079. doi:10.1001/jamanetworkopen.2026.30083
By |2026-09-23T00:05:41-07:00Sep 25, 2026|Infectious Disease, Pediatrics, Pulmonary|

Sickle Cell Acute Pain Episodes: Lessons Learned from the Prematurely Halted PECARN STArT Trial

A faces pain-assessment sheet and a prepared syringe on an overbed tray table, with an adolescent patient resting on the stretcher behind, in a pediatric emergency department

Article reviewed: Morris CR, Hatabah D, Korman R, et al. Arginine therapy for sickle cell disease acute pain episodes: the STArT randomized clinical trial. JAMA. Published online August 19, 2026
DOI: 10.1001/jama.2026.13310  |  PubMed: PMID 42616542

A child with sickle cell disease arrives in your emergency department (ED) in an acute pain episode. In one of the largest US pediatric trials of a treatment for acute sickle cell pain, how long that crisis lasted varied far more between hospitals than it did between the study drug and placebo.

The PECARN STArT trial randomized 274 children and young adults with sickle cell acute pain episodes to IV arginine or saline placebo at 10 US children’s hospitals. Arginine, which targets the nitric oxide depletion that drives vaso-occlusion, did not shorten time to crisis resolution, and the trial was halted early for futility [1]. The more useful numbers are in site-level data. Median time to crisis resolution varied by as much as 61 hours between participating hospitals, and mean total parenteral opioid by as much as 3.0 mg/kg of based on morphine-equivalent calculations [1,3]. These are observational site differences. They may reflect analgesia and opioid-discontinuation practice, patient mix, and other institutional factors that the analyses can not distinguish.

Study Design

STArT was a double-blind, placebo-controlled phase 3 randomized clinical trial conducted (2021-2024). Patients aged 3 to 21 years with sickle cell disease who presented to the ED with acute pain requiring parenteral opioids and hospital admission were randomized within 12 hours of their first IV opioid dose. Arginine was given as a 200 mg/kg loading dose followed by 100 mg/kg every 8 hours until discharge. Of 274 patients randomized, 271 received study drug, 129 arginine and 142 placebo. The primary outcome was time to crisis resolution, the interval from first study drug delivery to the last dose of parenteral opioid, and it is the outcome the US Food and Drug Administration prefers for regulatory approval in this population [1].

Results

Median time to crisis resolution was 60.8 hours with arginine versus 65.8 hours with placebo, an absolute difference of 7.2 hours favoring arginine with a confidence interval spanning benefit in either direction (95% CI, -21.6 to 35.9 hours). Total parenteral opioid use, pain scores, and hospital length of stay were similar between groups, and the arginine effect on time to crisis resolution did not differ significantly by chronic pain status. Serious adverse events did not differ and there were no deaths [1].

Three descriptive findings arose from the collected data:

  • Site variation. Median time to crisis resolution differed by up to 61 hours across the 10 hospitals, and mean total parenteral opioid by up to 3.0 mg/kg [1,3].
  • Delay to study drug. Study drug arrived a median of 8 hours after the first ED dose of IV opioid, and only 50.4% of participants had sought care within 24 hours of pain onset [1]. In 23 of 271 treated participants the last IV opioid had already been given before study drug arrived, producing a primary outcome of zero hours.
  • Chronic pain prevalence. 41% of participants met criteria for chronic sickle cell pain, including 34% of children younger than 12 years [1]. A single triage pain score means something different in a child who already has pain 15 or more days a month.

Build an Expedited Pain Plan in the Emergency Department

It is unclear why the wide variation in time to pain crisis resolution. The study was not designed to untangle the reasons, but in theory the causes are likely multifactorial and include: patient mix, underlying chronic pain, time spent in pain before arrival, institutional practices, and individual practitioner analgesia practices. That last one is something that you can act on today.

An expedited pain plan for a sickle cell acute pain episode

Consider administering intranasal fentanyl at triage, if  IV opioids are not readily available.

The American Society of Hematology 2020 recommendation is to assess the patient and administer analgesia within 1 hour of ED arrival, with reassessment every 30 to 60 minutes. It is a strong recommendation on low-certainty evidence [8].

Two cross-sectional PECARN studies describe what meeting those targets looks like. In a PECARN Registry analysis of 9233 ED visits for uncomplicated sickle cell pain at 12 children’s hospitals, a first opioid dose within 60 minutes of arrival was associated with lower odds of hospitalization (OR 0.84; 95% CI, 0.75-0.95). That association held even when the second dose fell outside 30 minutes (OR 0.85), and with a timely first dose the odds fell stepwise as the second-dose interval shortened: 0.78 within 60 minutes, 0.70 within 45, and 0.62 within 30 (95% CI, 0.52-0.75) [9]. Separately, among 400 children at 20 academic pediatric EDs in the US and Canada, only 19% received intranasal fentanyl, and those who did had nearly ninefold higher adjusted odds of discharge from the ED (adjusted OR 8.99; 95% CI, 2.81-30.56; P < .001) [10].

Both studies are cross-sectional and neither establishes causality. Timeliness of the first dose is the more robust of the two signals, since it survived a late second dose.

Not All Pain is the Same

The STArT study enrolled acute pain episodes, defined by pain severe enough to need parenteral opioids. However, arginine specifically targets vaso-occlusion pain. The accompanying JAMA editorial argued that these are not the same thing: the term acute pain episode has become operationally synonymous with vaso-occlusive episode, yet acute pain in sickle cell disease also arises from neuropathic mechanisms, central sensitization, and musculoskeletal injury [2]. A trial that heterogeneously enrolls all of them dilutes the study population. Notably, 41% of the study participants had underlying chronic pain [1].

Can We Narrow the Patient Inclusion Criteria?

The editorial accompanying STArT argues for enrolling a more narrow subset of patients, focusing on objective markers rather than pain severity [2]:

  • Hypoxemia, worrisome for acute chest syndrome
  • Very high LDH with thrombocytopenia, reported in a small retrospective adult series as suggesting a severe vaso-occlusive subtype that prompted consideration of early intervention [6]
  • Acute kidney injury or acute liver injury, used the way organ dysfunction defines severity in sepsis trials
Trial design sidebar
Why the trial stopped early, and why that matters beyond arginine

STArT closed after 76.1% of target enrollment because conditional power for the primary outcome had fallen below 6%, even assuming the full 17-hour effect originally hypothesized. Futility stopping is not a safety signal, and it is not proof of no effect. It means the predicted chance of reaching the primary statistical result was low if enrollment continued, not zero [1].

The primary outcome measure is a possible culprit. Time to crisis resolution correlated with hospital length of stay, which can be shaped as much by institutional opioid discontinuation practice as by drug biology [1,2,7]. US stays have trended shorter over the last 25 years and are now brief: the editorial describes a contemporary median under 72 hours, and PECARN’s MAGiC trial reported a median under 56 hours [1,2,5]. A post hoc recalculation using STArT’s own variance estimates put the required sample size above 900 participants [1]. Morris et al note that phase 3 trials targeting acute sickle cell pain have so far failed to shorten either hospital length of stay or time to crisis resolution [1], despite the study drugs spanning four largely distinct mechanisms: inhaled nitric oxide in 2011 [11], IV magnesium in PECARN’s MAGiC trial in 2015[5], poloxamer 188 in 2021 [12], and rivipansel, an E-selectin antagonist, in 2023 [13]. Arginine is the fifth agent to move nothing on this family of endpoints. The authors now question the outcome measure itself.

Three levers are on the table. The first is to enroll patients with objective organ injury, where the endpoint can be adjudicated on an image or a laboratory value rather than on a clinician’s decision to stop an opioid infusion. Among 54 STArT participants who either had acute chest syndrome at presentation or developed it after randomization, mean time to crisis resolution was 108 hours with arginine versus 184 hours with placebo (29 vs 25 participants; P = 0.16; median difference 34 hours) [4]. Because acute chest syndrome status partly arose after randomization, this exploratory comparison cannot establish a treatment effect. The editorialists note that further detail from this cohort is awaited and would likely be informative [2]. The second is to change the outcome entirely. STArT captured 72-hour and 28-day ED return and rehospitalization as safety outcomes, and the editorialists argue these belong on the efficacy side, because the burden of sickle cell disease acute pain “may reside less in the duration of individual hospitalizations and more in the frequency of readmissions and ED revisits” [2]. The 28-day ED-return rates were 27.1% with arginine and 32.4% with placebo, and at a disease level return visits follow as many as 29% of initial ED encounters, with up to 28% of hospitalized children readmitted within 30 days [1]. The third lever is the design itself: the editorialists raise external control cohorts, or a crossover in which patients serve as their own controls, as ways to cut the participant numbers a conventional trial would need [2].

Bottom Line

  • Arginine is not ready. Nothing in this STArT trial displaces supportive care, NSAIDs, and opioids for a sickle cell acute pain episode.
  • The 61-hour spread between hospitals was more than three times the trial’s originally hypothesized 17-hour treatment difference. How your department assesses and treats pain is part of what that spread reflects.
  • The American Society of Hematology recommends giving an analgesic dose within the first hour of ED arrival. Consider intranasal fentanyl at triage, while awaiting IV access.

References

  1. Morris CR, Hatabah D, Korman R, et al; Pediatric Emergency Care Applied Research Network (PECARN). Arginine therapy for sickle cell disease acute pain episodes: the STArT randomized clinical trial. JAMA. Published online August 19, 2026. PMID: 42616542. doi:10.1001/jama.2026.13310
  2. Anum SJ, Kanter J. Arginine treatment and sickle cell disease pain: a great STArT, but a hard end point. JAMA. Published online August 19, 2026. PMID: 42616535. doi:10.1001/jama.2026.14849
  3. Rees CA, Hatabah D, Korman R, et al; PECARN. Hospital variations in time-to-crisis-resolution among children and adolescents with sickle cell disease. Am J Hematol. 2026;101(1):206-212. PMID: 41190764. doi:10.1002/ajh.70129
  4. Morris CR, Ahmad F, Airewele G, et al. Sickle cell disease treatment with arginine therapy (STArT): results of a phase-3 randomized controlled trial. Blood. 2025;146(suppl 1):616. doi:10.1182/blood-2025-616
  5. Brousseau DC, Scott JP, Badaki-Makun O, et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood. 2015;126(14):1651-1657. PMID: 26232172. doi:10.1182/blood-2015-05-647107
  6. Gardner K, Thein SL. Super-elevated LDH and thrombocytopenia are markers of a severe subtype of vaso-occlusive crisis in sickle cell disease. Am J Hematol. 2015;90(10):E206-E207. PMID: 26205137. doi:10.1002/ajh.24126
  7. Ataga KI. The challenge of clinical end points in sickle cell disease. Blood. 2023;142(24):2047-2054. PMID: 37890140. doi:10.1182/blood.2023021220
  8. Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv. 2020;4(12):2656-2701. PMID: 32559294. doi:10.1182/bloodadvances.2020001851
  9. Gwarzo I, Coleman KD, McKinley K, et al. Opioid timeliness in the emergency department and hospitalizations for acute sickle cell pain. JAMA Pediatr. 2025;179(11):1194-1202. PMID: 40892426. doi:10.1001/jamapediatrics.2025.2967
  10. Rees CA, Brousseau DC, Ahmad FA, et al; SCD Arginine Study Group and PECARN. Intranasal fentanyl and discharge from the emergency department among children with sickle cell disease and vaso-occlusive pain: a multicenter pediatric emergency medicine perspective. Am J Hematol. 2023;98(4):620-627. PMID: 36606705. doi:10.1002/ajh.26837
  11. Gladwin MT, Kato GJ, Weiner D, et al; DeNOVO Investigators. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA. 2011;305(9):893-902. PMID: 21364138. doi:10.1001/jama.2011.235
  12. Casella JF, Barton BA, Kanter J, et al. Effect of poloxamer 188 vs placebo on painful vaso-occlusive episodes in children and adults with sickle cell disease: a randomized clinical trial. JAMA. 2021;325(15):1513-1523. PMID: 33877274. doi:10.1001/jama.2021.3414
  13. Dampier CD, Telen MJ, Wun T, et al; RESET Investigators. A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis. Blood. 2023;141(2):168-179. PMID: 35981565. doi:10.1182/blood.2022015797
By |2026-09-10T14:44:05-07:00Aug 24, 2026|Heme-Oncology, Pediatrics, Tox & Medications|

PERC-Peds Rule Could Change How Children Are Evaluated for Pulmonary Embolism: A PECARN Study

Pediatric emergency clinician evaluating a child at bedside, no imaging equipment in frame

Article reviewed: Ellison AM, Kuppermann N, Shihabuddin BS, et al. PERC-Peds rule for bedside exclusion of pulmonary embolism without radiation in children in the USA (BEEPER): a multicentre, prospective, observational, diagnostic accuracy study. Lancet Respir Med. Published online July 2026
DOI: 10.1016/S2213-2600(26)00086-X

Pulmonary embolism (PE) in children is uncommon, but delayed or missed diagnosis can have serious consequences. Despite this, there is relatively little evidence to guide clinician evaluation of suspected pediatric PE. There are no validated pediatric PE rule-out strategies and adult diagnostic pathways have not been prospectively tested in children.

PECARN sought to change that with their recently published study – BEEPER: Bedside Exclusion of Pulmonary Embolism without Radiation in Children [1]. The investigators developed a rule that safely excluded PE in low-risk children.

Study Objective

The goal of BEEPER was to prospectively evaluate whether the Pulmonary Embolism Rule-out Criteria adapted for children (PERC-Peds) could safely exclude pulmonary embolism in children without the need for laboratory testing or imaging.

What is PERC-Peds?

PERC-Peds was adapted from the adult Pulmonary Embolism Rule-out Criteria (PERC), a well-established adult clinical decision rule used to exclude PE in low-risk patients without additional testing [2]. Using retrospective pediatric data, investigators modified the adult PERC rule to create the pediatric version. A child was considered PERC-Peds negative only if ALL of the following were true:

  • Clinician gestalt pretest probability <15%
  • No prior PE or proximal DVT
  • No surgery requiring intubation within 30 days
  • No current estrogen use
  • No hemoptysis
  • Heart rate always:
    • <100 beats/min if older than 12 years
    • <120 beats/min if 12 years or younger
  • Oxygen saturation consistently >94%
  • No suspected DVT

Study Design

A Large, Prospective, Multicenter PECARN Study

BEEPER was a multicenter, prospective observational diagnostic accuracy study conducted across 21 emergency departments within PECARN (the Pediatric Emergency Care Applied Research Network).

Inclusion Criteria:

  • 4–17 years old, AND
  • had suspected PE or proximal DVT prompting clinicians to:
    • order diagnostic testing, OR
    • strongly consider PE in the differential diagnosis

Eligible diagnostic testing included:

  • D-dimer
  • CT pulmonary angiography (CTPA)
  • V/Q scan
  • MRI angiography
  • Other pulmonary vascular imaging

All testing decisions remained entirely at clinician discretion.

Outcome Definition

The outcome was venous thromboembolism (VTE), including:

  • image-confirmed pulmonary embolism, OR
  • proximal DVT (above knee or elbow)

Results

Enrollment

  • 4,039 children enrolled, 3,988 had analyzable data

Prevalence of Disease

Overall:

  • 254 children (6.3%) had PE and/or proximal DVT

Breakdown:

  • Isolated proximal DVT: 76
  • Both PE and proximal DVT: 56
  • Isolated PE: 122

Performance of PERC-Peds

The PERC-Peds rule demonstrated extremely high diagnostic sensitivity.

Diagnostic Accuracy

  • Sensitivity: 99.6% (95% CI 97.8–99.9%)
  • Specificity: 19.6% (95% CI 18.4–21.0%)
  • False negative rate: 0.1% (95% CI 0–0.75%)
  • Negative predictive value: 99.9%

There was only ONE false negative. These findings suggest that PERC-Peds can safely exclude PE in a subset of low-risk children without additional laboratory testing or imaging.

D-Dimer Findings

BEEPER also provided the first large prospective evaluation of D-dimer performance in children undergoing PE evaluation. Clinicians ordered D-dimer testing in approximately 75–79% of enrolled children. Using a standardized threshold of 500 ng/mL:

  • Sensitivity: 88.8%
  • Specificity: 61.9%
  • False negative rate: 1.2–1.4%

These data support the use of D-dimer as part of a sequential diagnostic strategy in pediatric PE evaluation for those children who fail PERC-Peds.

PERC-Peds + D-Dimer Sequential Strategy

One of the most clinically important findings was the potential value of combining:

  • PERC-Peds
  • followed by D-dimer if PERC-Peds failed

This sequential strategy would have:

  • safely excluded PE in 54.7% of enrolled children,
  • excluded PE in 69% of children who had D-dimer ordered,
  • maintained an acceptable false negative rate of 1.0% (95% CI 0.6–1.5%),
  • estimated reduction in CT pulmonary angiography use by approximately 18.5%.

Putting PERC-Peds in Context

The PERC-Peds rule performed well compared to the regularly utilized adult PERC rule. Adult PERC studies [2] typically show sensitivities around 95% with false negative rates below 2%, while in BEEPER, the sensitivity approached 100% with an exceptionally low false negative rate. Just as importantly, this is the first prospective study to support a bedside rule-out strategy for PE in children: offering a potential pathway to safely reduce unnecessary CT scans and radiation exposure in low-risk patients. BEEPER also lays the groundwork for a more standardized pediatric PE evaluation approach, where clinicians could use PERC-Peds first, followed by D-dimer testing when needed, reserving imaging for children at higher risk.

What’s Next?

While BEEPER represents a major step forward in pediatric PE diagnosis, the study also highlights important limitations and unanswered questions. PERC-Peds demonstrated high sensitivity, but relatively low specificity: meaning many children will still fail the rule, and indiscriminate use could potentially increase testing. Importantly, BEEPER was an observational diagnostic study, meaning it did not evaluate outcomes from the implementation of a clinical decision rule.

BEEPER provides the foundation for a new era of pediatric PE evaluation research. Future studies will likely focus on implementation science: understanding whether use of PERC-Peds changes clinician behavior, safely reduces imaging, and can be integrated into real-world emergency department workflows. Investigators also envision future diagnostic algorithms that combine PERC-Peds with D-dimer testing to reserve imaging for children at highest risk, potentially reducing unnecessary radiation exposure in a meaningful number of patients. Additional work can evaluate performance across different clinical settings, refine the gestalt component of the rule, and explore integration into electronic health record decision support tools. Taken together, BEEPER fills one of the most important evidence gaps in pediatric emergency medicine and represents the first major step toward safer, more standardized, and evidence-based pediatric PE evaluation.

References

  1. Ellison AM, Kuppermann N, Shihabuddin BS, et al. PERC-Peds rule for bedside exclusion of pulmonary embolism without radiation in children in the USA (BEEPER): a multicentre, prospective, observational, diagnostic accuracy study. Lancet Respir Med. Published online July 2026. doi:10.1016/S2213-2600(26)00086-X.
  2. Kline JA, Courtney DM, Kabrhel C, et al. Prospective multicenter evaluation of the pulmonary embolism rule-out criteria. J Thromb Haemost. 2008;6(5):772-780. doi:10.1111/j.1538-7836.2008.02944.x. PMID: 18318689.
By |2026-07-20T21:50:18-07:00Jul 21, 2026|Pediatrics, Pulmonary, Radiology|

What We Still Do Not Know About Pediatric Mental Health Emergencies: PECARN Research Agenda

Adolescent sitting on an emergency department bed seen from behind, with a caregiver and clinician nearby in a calm, dimly lit room

Article reviewed: Hoffmann JA, Foster AA, Krass P, et al. A research agenda for acute pediatric mental and behavioral health emergencies. Ann Emerg Med. Published online July 10, 2026
DOI: 10.1016/j.annemergmed.2026.05.015  |  PubMed: PMID 42429726

Every emergency physician knows these moments. A 10-year-old with autism is escalating in a hallway bed, and nobody can say which de-escalation approach or which medication is safest for him. A 15-year-old is boarding for a third night after a suicide attempt, receiving no active treatment while she waits for a psychiatric bed. A charge nurse asks whether universal suicide screening is worth the workflow disruption. These are routine clinical decisions, and for most of them the pediatric evidence simply does not exist.

A new consensus statement from the PECARN Mental Health Working Group, A Research Agenda for Acute Pediatric Mental and Behavioral Health Emergencies, published in Annals of Emergency Medicine, maps where those evidence gaps are and which ones matter most [1]. The panel reached consensus on 51 research priorities, 31 of them top tier. Read as a whole, the agenda is an unusually honest inventory of how much of current pediatric behavioral health emergency care runs on extrapolation and local habit.

Background

One in 6 US children has a mental or behavioral health condition, and nearly half receive no treatment from a mental health professional [2]. The ED has become the de facto safety net: visits for self-harm and harm to others have risen substantially over the past decade, boarding times have stretched, and in 2021 the American Academy of Pediatrics, the American Academy of Child and Adolescent Psychiatry, and the Children’s Hospital Association jointly declared a national emergency in child and adolescent mental health [3]. What has not kept pace is the evidence for what emergency clinicians should actually do during these visits.

How the Agenda Was Built

The working group used a modified Delphi process with 23 expert partners: 4 parents and 1 young adult with lived experience of pediatric mental health emergency care, general and pediatric emergency physicians, emergency nurses, child and adolescent psychiatrists with emergency expertise, ED social workers, out-of-hospital and EMS-fellowship-trained clinicians, and a research funder. Across 3 survey rounds, 76 literature-informed candidate priorities were modified, expanded, and rated on need and urgency, research impact, and family centeredness. The prespecified retention criteria required agreement from both the family representative group and the clinician and funder group, so family voices could not be outvoted. The result: 51 consensus priorities sorted into 3 tiers.

Where the Gaps Are

Suicide prevention dominates

Suicide prevention questions account for 42% of the top tier. The panel wants to know which suicide risk screening tool best predicts real outcomes such as return visits, attempts, and deaths, including in neurodivergent children and non-English speakers; what universal screening does to those outcomes; and whether safety planning, with or without structured follow-up calls, actually increases mental health follow-up and reduces future attempts in youth. The contrast with adult evidence is striking. In adults, the multicenter ED-SAFE trial showed that universal screening plus a brief intervention reduced post-discharge suicidal behavior [4]. The pediatric equivalent has never been done. The panel also prioritized a practical lethal-means question: which safety devices, from medication lock boxes to firearm safes, do caregivers actually prefer and use after the ED visit?

Agitation: everything is still an open question

Which de-escalation methods best reduce medication use, restraint use, and staff injuries, and how does that differ by age, developmental stage, culture, language, and trauma history? Which medications are safest and most effective, for which children? What works for children with neurodevelopmental disorders such as autism spectrum disorder, who face a higher risk of pharmacologic and physical restraint? None of these have comparative evidence today, even though documented racial disparities in restraint application make the stakes plain [1].

Boarding and ED care

Top-tier questions include whether brief therapy delivered in the ED during boarding improves symptoms, shortens length of stay, and lowers admission rates, and whether home-based care is a safe and acceptable alternative to hospitalization. The panel also flagged care in rural and low-resource EDs, where most of these children are actually seen.

Before and after the ED

Out-of-hospital priorities center on training first responders in de-escalation and trauma-informed care and on testing novel response models, including mental health co-response teams and alternative destinations. A single-county pilot of direct EMS transport to a psychiatric emergency facility found that roughly 2 in 5 encounters met criteria for direct transport, with only 0.5% requiring secondary ED transfer within 24 hours [5]. On the back end, the agenda targets the high-risk post-discharge window: what actually gets youth to mental health care after they leave, and whether stepped-care models using telehealth reduce return visits and future attempts.

Clinical Implications

Nothing in a research agenda changes tomorrow’s orders, and this post will not pretend otherwise. The value for a practicing clinician is different. First, the agenda names how thin the floor is under common practices: medication choice for acute agitation in children, for example, is largely extrapolated from adult psychiatry. Knowing where evidence is absent should make us slower to treat local protocol as settled science. Second, this document signals where PECARN and federal funders will direct pediatric emergency mental health research over the next 5 to 10 years, which is useful for anyone building a QI program, a research career, or a departmental protocol they would prefer not to rewrite twice. Third, the top-tier questions double as an audit checklist: if your ED cannot say how often it restrains children, whether safety planning happens before discharge, or what its mental health boarding times are, the agenda is a reasonable place to start measuring.

One limitation deserves mention because the authors themselves flag it: no expert partners identified as Black or Hispanic, a notable gap given the documented racial disparities in restraint use and in behavioral health triage that PECARN’s own work has described.

Bottom Line

PECARN’s consensus research agenda distills the pediatric mental and behavioral health emergency evidence gap into 51 prioritized questions, with suicide prevention accounting for 42% of the top tier. It will not change your practice today. It tells you something more uncomfortable and more useful: for most of what we do during pediatric behavioral health visits, from de-escalation to safety planning to boarding care, the evidence base has not been written yet, and this is the field’s official to-do list for writing it.

References

  1. Hoffmann JA, Foster AA, Krass P, et al. A research agenda for acute pediatric mental and behavioral health emergencies. Ann Emerg Med. Published online July 10, 2026. PMID: 42429726. doi:10.1016/j.annemergmed.2026.05.015
  2. Bitsko RH, Claussen AH, Lichstein J, et al. Mental health surveillance among children – United States, 2013-2019. MMWR Suppl. 2022;71(2):1-42. PMID: 35202359. doi:10.15585/mmwr.su7102a1
  3. American Academy of Pediatrics, American Academy of Child and Adolescent Psychiatry, Children’s Hospital Association. AAP-AACAP-CHA declaration of a national emergency in child and adolescent mental health. 2021.
  4. Miller IW, Camargo CA Jr, Arias SA, et al. Suicide prevention in an emergency department population: the ED-SAFE study. JAMA Psychiatry. 2017;74(6):563-570. PMID: 28456130. doi:10.1001/jamapsychiatry.2017.0678
  5. Glomb NW, Trivedi T, Grupp-Phelan J, et al. Safety of a prehospital emergency medical services protocol for an alternative destination for pediatric behavioral emergencies in Alameda County. J Am Coll Emerg Physicians Open. 2023;4(2):e12930. PMID: 37051504. doi:10.1002/emp2.12930
By |2026-07-13T03:11:42-07:00Jul 13, 2026|Pediatrics, Psychiatry|

AZ-SWED Trial: Azithromycin Does Not Improve Preschool Wheezing Outcomes

Pediatric emergency clinician listening to a wheezing toddler's chest with a stethoscope while the child sits on a parent's lap

Article reviewed: Denninghoff KR, Casper TC, Zorc JJ, et al. Azithromycin for Preschoolers with Wheezing in the Emergency Department. N Engl J Med. Published online May 18, 2026
DOI: 10.1056/NEJMoa2516505  |  PubMed: PMID 42149992

Preschool wheezing is one of the most common pediatric ED presentations, and reaching for azithromycin can be tempting. Rhinovirus is the virus most often detected in these episodes, but pathogenic bacteria are commonly found in the nasopharynx of affected children, and some earlier outpatient data suggested that early antibiotic therapy might blunt severity.

The AZ-SWED trial (Azithromycin Therapy in Preschoolers with a Severe Wheezing Episode Diagnosed at the Emergency Department), published in the New England Journal of Medicine, tested this directly in the ED. The trial was stopped early for futility [1].

Study Design

Denninghoff et al enrolled 840 children aged 18-59 months presenting with moderate-to-severe wheezing across eight PECARN emergency departments. The age range was chosen to target preschool-aged children before a clear asthma diagnosis is typically established, the population in whom antibiotic benefit has been most often hypothesized and in whom practice variation is greatest. Children were randomized to either a 5-day course of azithromycin or a matching placebo, with all participants also receiving standard care at the treating clinician’s discretion, including bronchodilators and corticosteroids.

Because prior research raised the possibility that bacterial co-colonization might identify a subgroup most likely to benefit from antibiotics [2-5], the trial pre-specified separate analyses for children with and without detectable nasopharyngeal Streptococcus pneumoniae, Moraxella catarrhalis, or Haemophilus influenzae, the three organisms most commonly implicated in respiratory illness in this age group. This let the investigators test whether the bacteria-positive children benefit, rather than leaving it as a post hoc question.

The primary outcome was symptom severity over 5 days, measured using the Asthma Flare-up Diary for Young Children (ADYC), a validated 17-item caregiver-reported instrument in which each symptom is scored from 1 (best) to 7 (worst) [6]. Secondary outcomes included ED and hospital length of stay and return ED visits or hospitalizations within 72 hours [1].

Results

Azithromycin provided no clinical benefit over placebo, regardless of bacterial detection status.

ADYC symptom scores over 5 days were similar between groups in children with detectable nasopharyngeal bacteria (p = 0.70) and in those without (p = 0.69). There were no meaningful differences in length of stay or in return visits or hospitalizations.

Rhinovirus was the most commonly detected virus, identified in 72.5% of participants. Pathogenic bacteria were detected on nasopharyngeal swab in 62% of children overall. Azithromycin did clear nasopharyngeal bacteria more effectively than placebo (58.7% vs 11.4%), confirming that the drug was biologically active. That microbiologic effect, however, did not translate to clinical improvement on any outcome measured.

Clinical Implications

This is a large, ED-based randomized trial, and it argues against routine antibiotic use in preschool wheezing. Up to a quarter of children hospitalized for wheezing currently receive antibiotics, which likely reflects the same uncertainty the trial set out to address. The bacteria detected in the nasopharynx do not appear to drive the acute wheezing episode in these children, and treating them does not change how the children do.

The dissociation between bacterial clearance and clinical outcomes is itself informative. The fact that azithromycin reliably eradicated nasopharyngeal bacteria without any detectable clinical signal suggests that these organisms are bystanders rather than drivers of the acute episode, at least in most preschool wheezers. This has implications beyond this trial: it cautions against using bacterial detection alone as a rationale for antibiotic prescribing in this age group.

Bottom Line

Routine azithromycin has no role in the management of preschool wheezing, even in children with detectable nasopharyngeal bacteria. Bronchodilators and corticosteroids where appropriate remain the mainstays of care, and these data give clinicians another reason to hold antibiotics in this group.

References

  1. Denninghoff KR, Casper TC, Zorc JJ, et al. Azithromycin for Preschoolers with Wheezing in the Emergency Department. N Engl J Med. Published online May 18, 2026. PMID: 42149992. doi:10.1056/NEJMoa2516505
  2. Bisgaard H, Hermansen MN, Buchvald F, et al. Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med. 2007;357(15):1487-1495. PMID: 17928596. doi:10.1056/NEJMoa052632
  3. Bacharier LB, Guilbert TW, Mauger DT, et al. Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized Clinical Trial. JAMA. 2015;314(19):2034-2044. PMID: 26575060. doi:10.1001/jama.2015.13896
  4. Stokholm J, Chawes BL, Vissing NH, et al. Azithromycin for episodes with asthma-like symptoms in young children aged 1-3 years: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2016;4(1):19-26. PMID: 26704020. doi:10.1016/S2213-2600(15)00500-7
  5. Mandhane PJ, Paredes Zambrano de Silbernagel P, Aung YN, et al. Treatment of preschool children presenting to the emergency department with wheeze with azithromycin: a placebo-controlled randomized trial. PLoS One. 2017;12(8):e0182411. PMID: 28771627. doi:10.1371/journal.pone.0182411
  6. Ducharme FM, Jensen ME, Mendelson MJ, et al. Asthma Flare-up Diary for Young Children to monitor the severity of exacerbations. J Allergy Clin Immunol. 2016;137(3):744-749.e6. PMID: 26341275. doi:10.1016/j.jaci.2015.07.028
By |2026-06-02T21:43:22-07:00Jun 4, 2026|Infectious Disease, Pediatrics, Pulmonary|

PEM POCUS Series: Pediatric Musculoskeletal Ultrasound

PEM POCUS pediatric musculoskeletal badge

Read this tutorial on the use of point of care ultrasonography (POCUS) for pediatric musculoskeletal evaluation. Then test your skills on the ALiEMU course page to receive your PEM POCUS badge worth 2 hours of ALiEMU course credit.

Module Goals

  1. List the indications for performing pediatric musculoskeletal (MSK) point-of-care ultrasound (POCUS)
  2. Describe the technique for performing specific pediatric MSK POCUS applications
  3. List anatomical landmarks for specific MSK POCUS applications
  4. Interpret signs of fracture, effusion, dislocation, and osteomyelitis with POCUS
  5. Describe the limitations of MSK POCUS

Case Introduction: Adolescent with Left Knee Swelling

A 13-year-old female with no past medical history presents to the emergency department with pain and swelling to her left knee. The pain started 3 days ago, with the pain worsening and swelling noted on the day prior to arrival. She can bear weight but has a limp. She has had no other current or past joint pain or swelling, no known trauma, no fever or other infectious symptoms, no recent travel, and no known insect or tick bites. She spent the summer at camp in the northeast United States. Her vaccines are up to date.

On arrival, her vital signs are:

Vital Sign Finding
Temperature 37.3 C
Heart rate 109 bpm
Blood pressure 117/74
Respiratory rate 20
Oxygen saturation (room air) 99%

On physical examination, she is well appearing and in no acute distress. Her exam is significant for left knee swelling and tenderness to palpation anteriorly with decreased knee flexion due to pain. She has no redness, warmth, or numbness around her knee. She has an antalgic gait but can bear weight.

Given her pain and swelling of her left knee, blood tests and X-rays are ordered, and orthopedics is consulted. You decide to perform a musculoskeletal point-of-care ultrasound (MSK POCUS) examination.

Musculoskeletal POCUS can be performed for a variety of indications including trauma, swelling, erythema, pain, decreased range of motion of a joint, and limp or inability to bear weight. It can assist in early diagnosis of fracture, effusion, dislocation, and osteomyelitis and allow for expedited treatment. Children and adolescents are ideal candidates for MSK POCUS as they generally have less subcutaneous tissue, making it easier to obtain ultrasound images to assess for pathology.

Note: This module focuses on diagnostic uses in musculoskeletal POCUS and not on procedural uses.

Musculoskeletal POCUS can be incorporated into the physical examination by scanning the area of injury, the point of maximal pain or tenderness, or a joint for effusion.

Probe Selection and Patient Comfort

Linear ultrasound probe

Figure 1. Linear ultrasound probe.

  • Use a high frequency linear probe (Figure 1) to obtain high resolution images of generally superficial structures in MSK POCUS.
    • A curvilinear probe may be necessary for older children to examine structures with depth greater than 4-6 cm (e.g., hip).
  • Patient comfort is the key to obtaining quality images.
    • Place in a position of comfort on the bed, chair, or in a parent’s lap.
    • Apply copious warm gel (Figure 2L).
    • Rest the base of your scanning hand on a non-tender area to avoid putting excessive pressure on a painful area (Figure 2R).
    • Provide pain control.
    • Distract with a toy, book, or phone/tablet.
    • Consult a child life specialist, if available, to help ease the child’s anxiety.
Linear probe with gel and floating probe technique

Figure 2. Linear probe with copious gel (L). The clinician floats the probe on the gel and rests the base of the scanning hand on an uninjured area to minimize pressure on the painful area (R).

Pro-Tips

  1. When performing MSK POCUS, it is helpful to scan the contralateral normal side first. This allows for identification of the child’s normal anatomy, including growth plates if present, and comparison when scanning the area of pain/injury. It also allows the child to understand the MSK POCUS exam before scanning the painful area.
  2. Match the probe footprint to the area being scanned: a wider, longer footprint for the hips or long bones; a smaller footprint for the small bones of the hands or feet.
Musculoskeletal POCUS is excellent at identifying fractures of long bones (e.g., radius and ulna); however, it is less reliable for identifying fractures at joints, epiphyses, and the small bones of the hands and feet, where curved, irregular contours make imaging with POCUS more difficult. Additionally, non-displaced physeal fractures (Salter-Harris I) may be missed by POCUS.

Technique

To evaluate for fracture, dislocation, or osteomyelitis, place a linear transducer over the desired area to identify changes to the bony contour or alignment.

  • Look everywhere. Scan bones circumferentially as much as possible and in perpendicular planes (longitudinal and transverse axes) to avoid missing pathology. Fractures may escape detection if the transducer is placed parallel to the course of the fracture.
  • Scan the contralateral side for comparison. This is especially crucial when the pathology involves or is adjacent to a physis.
  • Use the water bath technique. Submerge the injured extremity in a basin of water to facilitate imaging of the small bones of the hands and feet (Figure 3). The probe does not need to be in contact with the injured area in a water bath, and the probe is submersible up to the point where the electrical cord exits the probe.
Water bath technique to image a phalanx dorsally and ventrally with the submerged probe floating above the hand

Figure 3. Water bath technique to image a phalanx dorsally (L) and ventrally (R), with the submerged probe floating just above but not touching the injured hand.

Normal finger phalanx imaged with water bath technique

Figure 4. Normal finger phalanx imaged with the water bath technique, with the probe not touching the finger and approximately 1 cm of anechoic fluid between the probe and the finger. Air bubbles may be visible in the water.

Figure 5. Ultrasound clip of a normal finger phalanx using the water bath technique.

Normal Findings

Normal bone is seen as a hyperechoic line with posterior acoustic shadowing.

Normal physis:

  • Longitudinal view (Figure 6): Appears as a V-shaped, hypoechoic, uniform band of cartilage between the metaphysis and epiphysis that is symmetric with the contralateral side.
  • Transverse view (Figure 7): Appears as a regular but ragged area between the hyperechoic curvilinear metaphysis and epiphysis of the bone.

Longitudinal view of normal physis showing V-shaped hypoechoic band between metaphysis and epiphysis

Figure 6L. Longitudinal view of a normal physis. The hypoechoic band of cartilage forms a smooth V-shape between the hyperechoic metaphysis and epiphysis (yellow arrows: physis above, bone below). Compare with the contralateral side to confirm symmetry.

Figure 6R. Longitudinal scanning of a normal physis.

Transverse view of normal physis with regular but ragged appearance between metaphysis and epiphysis

Figure 7L. Transverse view of a normal physis. The cartilage band appears regular but ragged between the curvilinear hyperechoic metaphysis and epiphysis (yellow arrows: physis above, bone below).

Figure 7R. Transverse scanning of a normal physis.

Ultrasonography can reliably detect diaphyseal (long bone) fractures including the forearm, lower leg, and clavicle. It is also useful for detection of other fractures.

1. Long Bone Fracture

  • Longitudinal view (Figure 8): A fracture is visualized as a disruption in the bony cortex with a discontinuity or step-off. There may be associated periosteal changes, periosteal fluid, or hematoma. Angulation and displacement of the fracture fragments may be measured.
  • Transverse view (Figure 9): The fracture site is identified by an irregularity in the hyperechoic, curvilinear bony cortex and/or a “jump” in the location of the bone as the fracture site is crossed.
  • Ultrasound can detect fractures as small as 1 mm [1].
  • In the forearm and lower leg, be sure to scan both bones at the site of injury to avoid missing a fracture.

Pediatric distal radius fracture in longitudinal view showing cortical step-off with physis distal to the fracture

Figure 8L. Forearm fracture in longitudinal view. An angulated, displaced distal radius fracture is shown, with the physis visible distal to the fracture site.

Figure 8R. Longitudinal scanning of a distal radius fracture.

Pediatric distal radius fracture in transverse view showing irregular curvilinear bony surface with both edges of the fracture site visible

Figure 9L. Forearm fracture in transverse view. The fracture site shows an irregular curvilinear bony surface with both edges of the fracture visible.

Figure 9R. Transverse scanning of a distal radius fracture.

2. Buckle Fracture

  • A buckle fracture appears as a small “bump” in the linear bone cortex, usually without any discontinuity of the bone (Figure 10).

ultrasound finger fracture

Figure 10L. Two examples of buckle fracture of the distal radius (arrows). Top: small “bump” in the bony cortex without discontinuity. Bottom: a second buckle fracture of the distal radius in longitudinal view.

Figure 10R. Buckle fracture of the distal radius.

3. Finger Phalanx Fracture

  • The discontinuity of the cortex of a phalanx may be seen in longitudinal and transverse views (Figures 11 and 12).
  • A fracture appears as a break in the hyperechoic cortex, in contrast to a joint, which is regular and similar to adjacent fingers or to the contralateral normal side.

Pediatric finger phalanx fracture imaged in a water bath showing discontinuity of the bony cortex with FRACTURE and JOINT labeled

Figure 11. Discontinuity of the bony cortex of the phalanx (arrow) in a water bath, consistent with fracture. The adjacent joint is regular and intact.

Figure 12L. Longitudinal scanning of a phalanx fracture.

Figure 12R. Transverse scanning of a phalanx fracture.

4. Metacarpal Fracture

  • The discontinuity of the cortex of a metacarpal may be seen in longitudinal and transverse views (Figure 13).

Figure 13L. Cortical discontinuity (arrow) in a metacarpal fracture, with periosteal fluid (asterisk) adjacent to the fracture site.

Figure 13R. Scanning of a metacarpal fracture.

5. Nasal Fracture

  • The nasal bones may be identified, with fractures appearing as a discontinuity of the bone (Figures 14, 15, and 16). Use copious gel to facilitate imaging in this superficial, highly curved area and to minimize pain to the affected area.

Linear ultrasound probe positioning to evaluate for a pediatric nasal fracture

Figure 14. Linear probe positioning to evaluate for a nasal fracture.

Transverse ultrasound of a normal pediatric nasal bone (L) and a pediatric nasal fracture with cortical discontinuities indicated by yellow arrows (R)

Figure 15. Transverse view of a normal nasal bone (L) and a nasal fracture with cortical discontinuities (arrows, R).

Figure 16. Transverse scan of a nasal fracture.

6. Healing Fracture

  • Healing fractures will have a discontinuity in the bone with varying degrees of periosteal thickening and callus formation (Figures 17 and 18). The callus will be hypoechoic initially and will become more hyperechoic over time.

Longitudinal ultrasound of a healing distal radius fracture with periosteal thickening and callus

Figure 17L. Healing distal radius fracture in longitudinal view, with periosteal thickening and callus formation.

Figure 17R. Longitudinal scan of a healing distal radius fracture.

Transverse ultrasound of a healing distal radius fracture with periosteal thickening and callus

Figure 18L. Healing distal radius fracture in transverse view, with periosteal thickening and callus formation.

Figure 18R. Transverse scan of a healing distal radius fracture.

For evaluation of a joint effusion, the linear or curvilinear transducer is used to identify anechoic or hypoechoic fluid in the joint space. POCUS identifies the effusion but cannot distinguish hemorrhagic, infectious, or inflammatory etiologies; labs and/or advanced imaging are needed for further work-up.

POCUS of the lower extremity can assess for hip, knee, or ankle effusions. Findings must be interpreted with the clinical presentation and physical examination. For hip effusions, the Kocher criteria may be used to evaluate for septic hip.

1. Hip

  • See the ALiEM module on POCUS: Hip Effusion for more detail.
  • Positioning and probe placement: With the child’s leg in slight external rotation, place the linear transducer on the anterior hip parallel to the long axis of the femoral neck. Point the probe marker toward the patient’s head (Figure 19L).
  • Normal findings
    • Identify the hyperechoic curvilinear femoral head (+/- physis), hyperechoic linear femoral neck, and the posterior surface of the iliopsoas muscle (Figure 19R).
    • Look for fluid/effusion between the femoral neck and the posterior surface of the iliopsoas muscle. Normally a femoral fat pad sits in this space.

Linear ultrasound probe positioning on the anterior hip (L) and normal hip anatomy showing the femoral head with open physis, femoral neck, and iliopsoas muscle (R)

Figure 19. Linear probe positioning to evaluate for hip effusion (L) and normal hip anatomy (R). The arrow points to the femoral head physis.

Figure 20. Longitudinal scanning of a normal hip.

  • Abnormal finding: Hip effusion
    • Location: Anechoic or hypoechoic fluid located between the femoral neck and the iliopsoas muscle (Figure 21).
    • Measurement: A convex fluid collection measuring >5 mm (or >2 mm difference from the contralateral normal side) is positive for a hip effusion.
      • There is debate regarding measurement technique for hip effusion, with measurement of the hypoechoic fluid directly vs. measurement from the anterior surface of the femoral neck to the posterior surface of the iliopsoas muscle. However, clinically significant effusions will likely be positive (>5 mm) regardless of measurement technique, and asymmetry compared to the contralateral normal hip will usually be evident.

Hip effusion with anechoic fluid layering over the femoral neck measured to 5.7 mm, with femoral head, open physis (arrow), and iliopsoas muscle (asterisk) visible

Figure 21. Hip effusion with anechoic fluid layering over the femoral neck measured to 5.7 mm. Also visible are the femoral head with an open physis (arrow) and the iliopsoas muscle (*).

Figure 22. Longitudinal scanning of the hip showing a hip effusion.

2. Knee

  • Positioning and probe placement: Place the linear transducer longitudinally on the anterior distal femur, just superior to the patella, in the midline over the quadriceps tendon. Point the probe marker toward the patient’s head (Figure 23L). This single, longitudinal view of the suprapatellar bursa, which has direct communication with the knee joint, is the most sensitive for identifying a knee effusion (Figure 24). You may also fan the probe in longitudinal and transverse views to further evaluate the suprapatellar bursa for effusion.
    • Place a towel roll under the knee to provide about 30 degrees of knee flexion, the optimal position for detecting a knee effusion.
    • Avoid excessive pressure: pressure from the probe can compress the suprapatellar bursa and mask a small effusion.
    • To avoid missing a small effusion, milk fluid downward, medially, and/or laterally toward the probe to push fluid into the suprapatellar bursa. Hold the probe lightly while doing this.

Linear probe positioning over the anterior distal femur with a towel under the knee (L) and normal knee anatomy showing quadriceps tendon, cartilage around the patella, and femur (R)

Figure 23. Linear probe positioning to evaluate for knee effusion. Note the towel under the knee for slight knee flexion (L). Normal knee anatomy showing the quadriceps tendon (arrows) and cartilage around the patella (asterisk) (R).

Anatomic diagram of the bursae of the knee, highlighting the suprapatellar bursa contiguous with the knee joint space

Figure 24. Normal bursae anatomy at the knee. The suprapatellar bursa is contiguous with the knee joint space [2].

Figure 25. Longitudinal scanning of a normal knee.

  • Normal findings
    • Identify the linear, hyperechoic distal femur (+/- physis), the patella, and the quadriceps tendon attaching to the patella (Figure 23R). There is a pre-femoral fat pad between the femur and the quadriceps tendon. Look for a fluid collection in this suprapatellar space.
    • The patella ossifies at approximately 3-6 years of age, so younger children may still have a cartilaginous patella. The patella appears hypoechoic and may not have posterior acoustic shadowing. Do not confuse the cartilaginous patella with a joint effusion.
  • Abnormal finding: Knee effusion
    • Location: Anechoic or hypoechoic fluid sits in the suprapatellar bursa between the femur and the quadriceps tendon (Figure 26).
    • Measurement: Fluid measuring >2 mm in height is positive for a knee effusion.

Figure 26. Two examples of a knee effusion with anechoic fluid (*) between the femur and the quadriceps tendon (L) and with measurement of effusion (R).

Figure 27. Longitudinal scanning of a knee effusion.

3. Ankle

  • Positioning and probe placement: Place the linear transducer in the longitudinal axis anteriorly over the ankle joint in the midline. Point the probe marker toward the patient’s head (Figure 28L) to evaluate the tibiotalar joint. The tibiotalar joint is the area most likely to identify an effusion. Interrogate the entire joint by fanning the probe in longitudinal and transverse views to avoid missing an effusion.
  • Normal findings
    • Identify the curvilinear hyperechoic lines with posterior acoustic shadowing of the tibia and talus bones and the “V” shape of the joint (Figure 28R).

Figure 28. Ankle POCUS: Linear probe positioning to evaluate for ankle effusion (L) and normal ankle anatomy with an arrow pointing to the tibiotalar joint space (R).

  • Abnormal finding: Ankle effusion
    • Anechoic or hypoechoic fluid is seen in the tibiotalar joint space (Figure 29).

Bilateral ankle POCUS comparison with normal left tibiotalar joint and an asterisk marking anechoic effusion in the right tibiotalar joint

Figure 29. Ankle POCUS of bilateral ankles showing an effusion (*) in the right tibiotalar joint compared with the normal left side.

Figure 30. Longitudinal scanning of an ankle effusion.

POCUS of the upper extremity can assess for elbow and shoulder effusions. When an elbow effusion is identified after trauma, radiography is typically needed to further characterize a fracture.

1. Elbow

  • Positioning and probe placement: With the child’s elbow flexed to 90 degrees, place the linear transducer over the posterior distal humerus in longitudinal and transverse views to visualize the olecranon fossa and the elbow posterior fat pad (Figure 31).

Linear ultrasound probe positioning on the posterior elbow in longitudinal (L) and transverse (R) orientations with the elbow flexed to 90 degrees

Figure 31. Linear probe positioning for performing POCUS of the elbow to evaluate the elbow posterior fat pad in longitudinal (L) and transverse (R) views.

  • Normal findings
    • Identify the hyperechoic cortex of the distal humerus and the olecranon fossa.
    • The normal posterior fat pad (PFP) sits in the olecranon fossa below the continuation of the distal humeral line in the longitudinal view and below the line connecting both edges of the olecranon fossa in the transverse view. The triceps muscle can be seen above the elbow joint (Figure 32).

Normal elbow POCUS in longitudinal (L) and transverse (R) views showing the posterior fat pad (PFP) sitting below the distal humeral line in the olecranon fossa, with triceps muscle above and humerus below

Figure 32. Elbow POCUS: Normal elbow anatomy in longitudinal (L) and transverse (R) views with the posterior fat pad (PFP) located under the distal humeral line (dotted line).

Figure 33. Scanning of a normal elbow in longitudinal (L) and transverse (R) views.

  • Abnormal finding: Elbow effusion
    • Elbow US has high sensitivity and moderate specificity for fracture, so a negative scan makes fracture unlikely.
    • Sonographic findings: The posterior fat pad is elevated above the distal humeral line in the longitudinal view, and above the line connecting both sides of the olecranon fossa in the transverse view (Figure 34). Lipohemarthrosis, i.e., blood and lipid material in the posterior fat pad, may appear as hypoechoic areas within the elevated fat pad (Figure 36).
    • Clinical significance: An elevated posterior fat pad and/or lipohemarthrosis is a marker of intracapsular elbow fracture, because the posterior fat pad sits intracapsular but extra-synovial.
      • Caution: The radial neck and medial epicondyle are extracapsular, so fractures at these sites may occur without an elevated posterior fat pad.
    • Application to nursemaid elbow: Annular ligament displacement (nursemaid elbow) does not usually produce a significant effusion or lipohemarthrosis. When the diagnosis is in question, a POCUS showing a normal posterior fat pad and no lipohemarthrosis may help rule out fracture and support proceeding with closed reduction.

Elbow effusion on POCUS with elevated posterior fat pad (PFP) rising above the distal humeral line in longitudinal view (L) and above the olecranon fossa line in transverse view (R), pushing up on the triceps muscle

Figure 34. Elevated posterior fat pad in longitudinal view rising above the distal humeral line (L) and transverse view rising above the line connecting both edges of the olecranon fossa (R). In both views, the posterior fat pad pushes up on the triceps muscle.

Figure 35. Scanning of an elbow effusion with an elevated posterior fat pad in longitudinal (L) and transverse (R) views.

Elbow POCUS showing elevated posterior fat pad with lipohemarthrosis marked by yellow asterisks in longitudinal (L) and transverse (R) views

Figure 36. Elbow POCUS: Elevated posterior fat pad with lipohemarthrosis (*) in longitudinal (L) and transverse (R) views.

2. Shoulder

  • Positioning and probe placement: Place the linear transducer in the transverse view over the posterior shoulder and point the probe marker laterally (Figure 37L).
  • Normal findings
    • Identify the hyperechoic curvilinear humeral head (+/- physis) and the hyperechoic glenoid (Figure 37R). The humeral head should be located in the glenoid fossa, with the humeral head and glenoid in the same horizontal plane.
  • Abnormal finding: Shoulder effusion
    • Anechoic fluid is seen around the humeral head within the glenohumeral joint (Figure 38).

Linear ultrasound probe positioning in the transverse view over the posterior shoulder (L) and corresponding normal shoulder anatomy showing humeral head, physis, and glenoid (R)

Figure 37. Shoulder POCUS: Linear probe positioning to evaluate for shoulder effusion (L) and the corresponding ultrasound view with normal shoulder anatomy (R).

Shoulder POCUS showing a shoulder effusion with anechoic fluid (asterisk) adjacent to the humeral head, with the physis indicated by an arrow

Figure 38. Shoulder POCUS: anechoic fluid (*) adjacent to the humeral head (L) and transverse scanning of the same effusion (R).

1. Shoulder Dislocation

  • Evaluate the relative positions of the glenoid and humeral head.
  • In a normal shoulder, the humeral head and glenoid should be in approximately the same horizontal plane (Figure 37R).
  • Anterior shoulder dislocation: The humerus is farther from the transducer and thus deeper on the ultrasound screen (Figure 39).
  • Posterior shoulder dislocation: The humerus is closer to the transducer and thus higher up on the ultrasound screen.
  • POCUS can be used to confirm relocation of the humerus into the glenoid fossa after a shoulder reduction.
Transverse shoulder POCUS demonstrating an anterior shoulder dislocation, with the glenoid labeled in the upper portion of the image and the humerus labeled deeper, indicating anterior displacement of the humeral head away from the posteriorly placed probe

Figure 39. Transverse view of an anterior shoulder dislocation: humeral head dislocated anteriorly, or farther away from the probe (L) and corresponding transverse scanning (R).

2. Finger Dislocation

  • In a finger dislocation, the bone malalignment at the interphalangeal joint can be seen (Figure 40).

Finger dislocation on POCUS with the probe positioned dorsally (L) showing the dorsal aspect of the interphalangeal joint and ventrally (R) showing the malaligned phalangeal bones with LEFT PINKY label

Figure 40. Finger dislocation with probe positioned dorsally (L) and ventrally (R).

Figure 41. Scanning of a finger dislocation: dorsal view (L) and ventral view (R).

  • Ultrasound findings of osteomyelitis may precede X-ray findings by several days.
  • Sonographic findings: Disrupted or irregular bony cortex, periosteal elevation and/or abscess, and increased vascular flow (Figure 42).

Osteomyelitis of the distal femur on POCUS showing irregular bony cortex with periosteal abscess marked by asterisk (L) and color Doppler showing increased vascular flow adjacent to the periosteal abscess (R)

Figure 42. Osteomyelitis of the distal femur with irregular bony cortex and periosteal abscess (*) (L) and increased vascular flow adjacent to the periosteal abscess (R).

Figure 43. Scanning of a distal femur with osteomyelitis: longitudinal view (L) and transverse view (R).

Figure 44. Longitudinal scanning of a distal femur with osteomyelitis showing increased vascularity on color Doppler.

Bony pathology that may be missed

MSK POCUS is excellent for long-bone fractures but is less reliable for fractures at joints, epiphyses, and the small bones of the hands and feet, whose curved, irregular contours are more difficult to image. Non-displaced physeal fractures (Salter-Harris I) and fractures <1 mm may also be missed. POCUS generally focuses on the area of injury and does not image the entire bone, so distant pathology can be missed.

Additionally, for elbow evaluation, radial neck and medial epicondyle fractures are extra-capsular and may occur without an associated effusion. A normal posterior fat pad on POCUS does not exclude these fractures. If a patient has tenderness at the radial neck or medial epicondyle, obtain further imaging.

Underlying pathology that cannot be characterized

POCUS can identify the presence of pathology such as a joint effusion or bone infection, but it cannot determine the etiology (e.g., hemorrhagic vs. infectious vs. inflammatory effusion). Further work-up, such as labs, joint aspiration, or advanced imaging, is needed to characterize the underlying process.

Image sharing across systems

Sharing POCUS clips within or between institutions can be cumbersome. Where feasible, archiving images to the medical record helps preserve diagnostic context for the broader healthcare team.

There have been several systematic reviews and meta-analyses on musculoskeletal POCUS applications.

Study Application N Sensitivity Specificity Comments
Morello et al, Eur J Pediatr 2024 [3] Distal forearm fractures 23 studies, 3,484 children 92–100% 85–100% Scoping review
Hassankhani et al, Skeletal Radiol 2024 [4] Clavicle fractures 7 studies, 1,255 patients 94% 98% Pediatric subset (4 studies, 863 children): Sn 96%, Sp 94%
Zhao et al, Medicine 2019 [5] Hand fractures 7 studies, 842 patients 91% 96% Fracture prevalence 39%
Tokarski et al, J Pediatr 2018 [6] Elbow fractures 6 studies, 512 children 96% 81% Fracture prevalence 48%
Gottlieb et al, Am J Emerg Med 2019 [7] Shoulder dislocation 7 studies, 739 patients 99% 99% Dislocation prevalence 41%; associated fracture: Sn 98%, Sp 99.8%

Table 1. Key systematic reviews and meta-analyses on musculoskeletal POCUS.

Other notable studies focusing on musculoskeletal POCUS include the following.

Pediatric Distal Forearm Fracture

The BUCKLED multicenter, noninferiority, randomized trial by Snelling et al enrolled 262 children ages 5–15 years with clinically non-angulated distal forearm injuries [8]. Children were randomized to POCUS or radiography. Those in the POCUS group with a cortical break identified also received radiography and usual care; buckle fractures were managed with a splint.

Results: At 4 weeks, physical function of the affected arm was non-inferior in the POCUS group. The POCUS group also had fewer X-rays, shorter emergency department length of stay, and higher patient satisfaction. The authors emphasized that physical function at 4 weeks is an important, real-world clinical outcome.

Joint Effusions

Adhikari and Blaivas compared POCUS with physical examination for the diagnosis of joint effusions [9]. They enrolled 54 adult patients with joint pain, erythema, and swelling.

Results: POCUS was more sensitive and accurate than physical examination. POCUS altered emergency department management in 65% of patients, either by avoiding an unnecessary joint aspiration or by identifying a clinically occult effusion.

Pediatric Hip Effusion

Jones et al conducted a multicenter prospective diagnostic study in children <18 years requiring radiology-performed hip ultrasound, comparing hip POCUS with the radiology study as the reference standard [10]. 161 children were enrolled by 18 PEM physicians, with 3 high-volume operators contributing 62% of cases.

Results: POCUS had an overall sensitivity of 94% and specificity of 98%. Among high-volume operators, sensitivity was 98% (specificity 98%); among low-volume operators, sensitivity was 83% (specificity 97%).

Case Resolution

A musculoskeletal POCUS of the left knee with a linear, high-frequency probe demonstrated a joint effusion in the suprapatellar bursa with internal septations (Figures 45 and 46).

Pediatric left knee POCUS composite showing suprapatellar joint effusion (L) and effusion with internal septations (R)

Figure 45. Left knee POCUS demonstrating a joint effusion in the suprapatellar bursa (L) and internal septations within the effusion (R).

Figure 46. Longitudinal scan of the left knee showing the joint effusion with internal septations.

Initial laboratory studies showed a white blood cell count of 10 × 109/L, ESR 69 mm/hr, and CRP 32 mg/L. Knee radiographs were negative for fracture. Orthopedics performed an arthrocentesis that yielded synovial fluid with 52,000 white blood cells/µL, raising concern for septic arthritis.

The patient was admitted, started on intravenous antibiotics, and taken to the operating room for incision, drainage, and washout. Joint fluid cultures returned negative, but Lyme serologies returned positive. She was transitioned to a 28-day course of doxycycline for Lyme arthritis.

Read more from this series → PEM POCUS Series

References

  1. Grechenig W, Clement HG, Fellinger M, Seggl W. Scope and limitations of ultrasonography in the documentation of fractures—an experimental study. Arch Orthop Trauma Surg. 1998;117(6-7):368-371. doi:10.1007/s004020050268. PMID: 9709853
  2. Wilson C. Suprapatellar bursitis: causes, symptoms, treatment & recovery. Knee Pain Explained. Published June 2, 2024. Accessed May 23, 2026. https://www.knee-pain-explained.com/suprapatellar-bursitis.html
  3. Morello R, Mariani F, Snelling PJ, Buonsenso D. Point-of-care ultrasound for the diagnosis of distal forearm fractures in children and adolescents: a scoping review. Eur J Pediatr. 2024;184(1):19. doi:10.1007/s00431-024-05877-w. PMID: 39548004
  4. Hassankhani A, Amoukhteh M, Jannatdoust P, Valizadeh P, Gholamrezanezhad A. A systematic review and meta-analysis on the diagnostic utility of ultrasound for clavicle fractures. Skeletal Radiol. 2024;53(2):307-318. doi:10.1007/s00256-023-04396-3. PMID: 37433884
  5. Zhao W, Wang G, Chen B, et al. The value of ultrasound for detecting hand fractures: a meta-analysis. Medicine (Baltimore). 2019;98(44):e17823. doi:10.1097/MD.0000000000017823. PMID: 31689869
  6. Tokarski J, Avner JR, Rabiner JE. Reduction of radiography with point-of-care elbow ultrasonography for elbow trauma in children. J Pediatr. 2018;198:214-219.e2. doi:10.1016/j.jpeds.2018.02.072. PMID: 29681446
  7. Gottlieb M, Holladay D, Peksa GD. Point-of-care ultrasound for the diagnosis of shoulder dislocation: a systematic review and meta-analysis. Am J Emerg Med. 2019;37(4):757-761. doi:10.1016/j.ajem.2019.02.024. PMID: 30797607
  8. Snelling PJ, Jones P, Bade D, et al; BUCKLED Trial Group. Ultrasonography or radiography for suspected pediatric distal forearm fractures. N Engl J Med. 2023;388(22):2049-2057. doi:10.1056/NEJMoa2213883. PMID: 37256975
  9. Adhikari S, Blaivas M. Utility of bedside sonography to distinguish soft tissue abnormalities from joint effusions in the emergency department. J Ultrasound Med. 2010;29(4):519-526. doi:10.7863/jum.2010.29.4.519. PMID: 20375371
  10. Jones RM, Malia L, Snelling PJ, et al. Diagnostic accuracy of point-of-care ultrasound for hip effusion: a multicenter diagnostic study. Ann Emerg Med. 2025;86(6):566-575. doi:10.1016/j.annemergmed.2025.04.033. PMID: 40481828
Go to Top